All In Biotech

Drug Trial Radar · NCT06351592

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Aug 28, 2024

Primary completion

Mar 21, 2032

Study completion Mar 21, 2032

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Apr 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * The effect the study drug has on specific biomarkers, which are substances in the blood or in the fluid that surrounds the brain and spinal cord, known as Cerebrospinal Fluid (CSF) * How much study drug is in the blood and in the CSF, at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * What effects the study drug has on ALS symptoms

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)
  • Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Interventions

  • ALN-SODDrug

    Administered per the protocol

  • DiluentOther

    Administered per the protocol

  • Placebo (PB)Drug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Event (TEAEs) in participants treated with ALN-SODTime frame: At week 4 and through week 228
  2. Severity of TEAEs in participants treated with ALN-SODTime frame: At week 4 and through week 228

Locations

22 sites in 9 countries. Site status is shown where the registry gives one.

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • Macquarie University

    Sydney, New South Wales, Australia · Recruiting

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia · Recruiting

  • KU Leuven

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • University of Alberta Hospital, Edmonton, Division of Neurology

    Edmonton, Alberta, Canada · Recruiting

  • University Hospital - London Health Sciences Centre

    London, Ontario, Canada · Recruiting

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada · Recruiting

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, Canada · Recruiting

  • Universitaetsklinikum Ulm AoR

    Ulm, Baden-Wurttemberg, Germany · Recruiting

  • Kyoto University Hospital

    Kyoto, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Tokushima University Hospital

    Tokushima, Tokushima, Japan · Recruiting

  • Toho University Omori Medical Center

    Ōta-ku, Tokyo, Japan · Recruiting

  • MTZ Clinical Research powered by Pratia

    Warsaw, Poland · Recruiting

  • Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Neurologii

    Krakow, Lesser Poland Voivodeship, Poland · Recruiting

  • Medical University of Silesia

    Zabrze, Silesian Voivodeship, Poland · Recruiting

  • Hanyang University Seoul Hospital

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Noorlands University Hospital-Department of Neurology

    Umeå, Noorland, Sweden · Recruiting

  • Karolinska University Hospital, Karolinska Institutet-ALS Center-Department of Clinical Neuroscience

    Huddinge, Stockholm County, Sweden · Recruiting

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.